Michael C. Wei

15.5k total citations · 8 hit papers
84 papers, 11.0k citations indexed

About

Michael C. Wei is a scholar working on Oncology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Michael C. Wei has authored 84 papers receiving a total of 11.0k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 33 papers in Pathology and Forensic Medicine and 22 papers in Molecular Biology. Recurrent topics in Michael C. Wei's work include Lymphoma Diagnosis and Treatment (32 papers), CAR-T cell therapy research (30 papers) and Chronic Lymphocytic Leukemia Research (18 papers). Michael C. Wei is often cited by papers focused on Lymphoma Diagnosis and Treatment (32 papers), CAR-T cell therapy research (30 papers) and Chronic Lymphocytic Leukemia Research (18 papers). Michael C. Wei collaborates with scholars based in United States, Canada and Australia. Michael C. Wei's co-authors include Stanley J. Korsmeyer, Tullia Lindsten, Solly Weiler, Emily H. Cheng, Atan Gross, Jennifer Jockel, Wei‐Xing Zong, Grant R. MacGregor, Vily Panoutsakopoulou and Kevin A. Roth and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Michael C. Wei

75 papers receiving 10.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death

2001 3.3k citations Michael C. Wei, Stanley J. Korsmeyer et al. profile →
BCL-2, BCL-XL Sequester BH3 Domain-Only Molecules Preventing BAX- and BAK-Mediated Mitochondrial Apoptosis

2001 1.4k citations Michael C. Wei, Stanley J. Korsmeyer et al. profile →
tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c

2000 1.0k citations Michael C. Wei, Stanley J. Korsmeyer et al. profile →
Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis

1998 937 citations Atan Gross, Jennifer Jockel et al. profile →
Caspase Cleaved BID Targets Mitochondria and Is Required for Cytochrome c Release, while BCL-XL Prevents This Release but Not Tumor Necrosis Factor-R1/Fas Death

1999 876 citations Atan Gross, Xiao Ming Yin et al. Journal of Biological Chemistry profile →
Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c

2000 827 citations Michael C. Wei et al. profile →
Occupancy-driven energy management for smart building automation

2010 424 citations Michael C. Wei et al. profile →
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

2022 244 citations Lihua E. Budde, Laurie H. Sehn et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael C. Wei United States	25	8.0k	2.3k	1.7k	1.4k	1.1k	84	11.0k
Masashi Narita United Kingdom	45	8.9k 1.1×	1.8k 0.8×	1.7k 1.0×	1.8k 1.3×	802 0.8×	104	13.1k
Frank C. Kuo United States	37	5.2k 0.7×	1.8k 0.8×	1.6k 1.0×	1.8k 1.3×	973 0.9×	86	12.1k
Gang Wang China	62	5.8k 0.7×	1.7k 0.7×	3.9k 2.3×	1.1k 0.8×	1.7k 1.6×	679	15.2k
Xin Chen China	58	6.6k 0.8×	2.2k 0.9×	1.0k 0.6×	1.1k 0.8×	1.4k 1.3×	382	11.7k
Masao Saitoh Japan	43	8.4k 1.0×	2.1k 0.9×	1.4k 0.8×	561 0.4×	1.3k 1.2×	115	11.1k
Min‐Liang Kuo Taiwan	66	7.6k 1.0×	3.8k 1.7×	2.0k 1.2×	863 0.6×	711 0.7×	191	13.1k
Zhi‐Nan Chen China	55	7.2k 0.9×	2.2k 1.0×	2.7k 1.6×	1.0k 0.8×	969 0.9×	349	11.2k
Wei‐Guo Zhu China	59	7.3k 0.9×	2.0k 0.9×	607 0.4×	1.8k 1.3×	702 0.7×	253	11.5k
Yiling Lu United States	64	11.6k 1.4×	3.5k 1.5×	1.4k 0.8×	907 0.7×	1.8k 1.7×	209	15.6k
Aik Choon Tan United States	56	6.8k 0.9×	4.5k 1.9×	1.3k 0.8×	698 0.5×	719 0.7×	262	12.1k

Countries citing papers authored by Michael C. Wei

Since Specialization

Citations

This map shows the geographic impact of Michael C. Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael C. Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael C. Wei more than expected).

Fields of papers citing papers by Michael C. Wei

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael C. Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael C. Wei. The network helps show where Michael C. Wei may publish in the future.

Co-authorship network of co-authors of Michael C. Wei

This figure shows the co-authorship network connecting the top 25 collaborators of Michael C. Wei. A scholar is included among the top collaborators of Michael C. Wei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael C. Wei. Michael C. Wei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lingwan, Maneesh, Michael C. Wei, Chunhui Xu, et al.. (2025). Persistent fatty acid catabolism during plant oil synthesis. Cell Reports. 44(4). 115492–115492. 2 indexed citations

Jamois, Candice, David C. Turner, Leonid Gibiansky, et al.. (2025). Tocilizumab Dosing for Management of T Cell‐Engaging Bispecific Antibody‐Related CRS in Patients With R/R B‐Cell NHL. Clinical Pharmacology & Therapeutics. 118(4). 917–927. 1 indexed citations

Bartlett, Nancy L., Laurie H. Sehn, Sarit Assouline, et al.. (2024). Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II. Blood. 144(Supplement 1). 1645–1645. 4 indexed citations

Budde, Lihua E., Sarit Assouline, Laurie H. Sehn, et al.. (2024). Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study. Journal of Clinical Oncology. 42(19). 2250–2256. 34 indexed citations

Assouline, Sarit, Lihua E. Budde, Julio C. Chávez, et al.. (2024). Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL).. Journal of Clinical Oncology. 42(16_suppl). 7021–7021.

Budde, Lihua E., Matthew J. Matasar, Laurie H. Sehn, et al.. (2024). Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma. Blood. 144(Supplement 1). 1646–1646. 4 indexed citations

Assouline, Sarit, Lihua E. Budde, Julio C. Chávez, et al.. (2024). Mosunetuzumab With Polatuzumab Vedotin: Subgroup Analyses in Patients (pts) With Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL). Clinical Lymphoma Myeloma & Leukemia. 24. S212–S212. 1 indexed citations

Schuster, Stephen J., Laurie H. Sehn, Nancy L. Bartlett, et al.. (2024). IBCL-335 Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients With Relapsed and/or Refractory Follicular Lymphoma After ≥2 Prior Therapies: 3-Year Follow-Up From a Pivotal Phase II Study. Clinical Lymphoma Myeloma & Leukemia. 24. S497–S497.

Wang, Xiaoyong, Tarec Christoffer El‐Galaly, Lale Kostakoglu, et al.. (2024). Automated Lugano Metabolic Response Assessment in ¹⁸ F-Fluorodeoxyglucose–Avid Non-Hodgkin Lymphoma With Deep Learning on ¹⁸ F-Fluorodeoxyglucose–Positron Emission Tomography. Journal of Clinical Oncology. 42(25). 2966–2977. 6 indexed citations

10.

Budde, Lihua E., Adam J. Olszewski, Connie Lee Batlevi, et al.. (2024). Characterizing the US Patient Population Receiving Rituximab with Gemcitabine and Oxaliplatin (R-GemOx) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Using Real-World Data. Blood. 144(Supplement 1). 2373–2373.

11.

Wei, Michael C., et al.. (2023). Intraoperative Ultrasound and Findings of Lumbar Intradural Disk Herniation Causing Cauda Equina Syndrome. World Neurosurgery. 179. 5–7. 1 indexed citations

12.

Schuster, Stephen J., Ling‐Yuh Huw, Christopher R. Bolen, et al.. (2023). Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas. Blood. 143(9). 822–832. 34 indexed citations

13.

Abramson, Vandana G., Mafalda Oliveira, Andrés Cervantes, et al.. (2019). A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. Breast Cancer Research and Treatment. 178(1). 121–133. 4 indexed citations

14.

Jager, Astraea, Pablo Domizi, Mara Pavel-Dinu, et al.. (2019). High-efficiency CRISPR induction of t(9;11) chromosomal translocations and acute leukemias in human blood stem cells. Blood Advances. 3(19). 2825–2835. 25 indexed citations

15.

Dickler, Maura N., Cristina Saura, Donald Richards, et al.. (2018). Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer. Clinical Cancer Research. 24(18). 4380–4387. 57 indexed citations

16.

Duque‐Afonso, Jesús, Kyuho Han, David W. Morgens, et al.. (2018). CBP Modulates Sensitivity to Dasatinib in Pre-BCR+ Acute Lymphoblastic Leukemia. Cancer Research. 78(22). 6497–6508. 12 indexed citations

17.

Leung, Vannessa, Michael C. Wei, & Timothy V. Roberts. (2018). Metastasis to the extraocular muscles: a case report, literature review and pooled data analysis. Clinical and Experimental Ophthalmology. 46(6). 687–694. 9 indexed citations

18.

Duque‐Afonso, Jesús, Michael C. Wei, Jue Feng, et al.. (2016). E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia. Cancer Research. 76(23). 6937–6949. 27 indexed citations

19.

Matheny, Christina, Michael C. Wei, Michael C. Bassik, et al.. (2013). Next-Generation NAMPT Inhibitors Identified by Sequential High-Throughput Phenotypic Chemical and Functional Genomic Screens. Chemistry & Biology. 20(11). 1352–1363. 57 indexed citations

20.

Gross, Atan, Xiao Ming Yin, Michael C. Wei, et al.. (1999). Caspase Cleaved BID Targets Mitochondria and Is Required for Cytochrome c Release, while BCL-XL Prevents This Release but Not Tumor Necrosis Factor-R1/Fas Death. Journal of Biological Chemistry. 274(2). 1156–1163. 876 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact